Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplantation (UMass Chan Medical School)
- Development stage
- Unknown
- Lead developer
- UMass Chan Medical School
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal
01
Overview
Fecal microbiota transplantation (FMT) is a biological therapy being investigated for the treatment of uncomplicated diverticulitis. It involves transferring fecal bacteria and other microbes from a healthy, screened donor into the recipient's gastrointestinal tract. [5, 9] The goal is to restore a healthy and diverse gut microbiome, which is often disturbed (dysbiosis) in patients with diverticular disease. [11, 2] A pilot study (NCT05373784) led by investigator Dr. J. Justin Maykel is assessing the feasibility, safety, and effectiveness of FMT administered via colonoscopy for preventing recurrence in patients with uncomplicated diverticulitis. [11] While FMT is an established and effective treatment for recurrent *Clostridioides difficile* infection (CDI), its use for diverticulitis is still considered experimental. [2, 11]
- Other names
- FMTFecal Microbiota Transplantfecal bacteriotherapy
Beyond the preview
Go deeper on fecal microbiota transplantation (UMass Chan Medical School).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplantation (UMass Chan Medical School).